Less Ads, More Data, More Tools Register for FREE

Pin to quick picksShield Thera Regulatory News (STX)

Share Price Information for Shield Thera (STX)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 2.05
Bid: 2.00
Ask: 2.10
Change: -0.10 (-4.65%)
Spread: 0.10 (5.00%)
Open: 2.15
High: 2.15
Low: 2.05
Prev. Close: 2.15
STX Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Holding(s) in Company

28 Jun 2017 10:37

RNS Number : 4170J
Shield Therapeutics PLC
28 June 2017
 

TR-1: NOTIFICATION OF MAJOR INTEREST IN SHARESi
 

1. Identity of the issuer or the underlying issuerof existing shares to which voting rights areattached: ii

SHIELD THERAPEUTICS PLC

2 Reason for the notification (please tick the appropriate box or boxes):

An acquisition or disposal of voting rights

ü

An acquisition or disposal of qualifying financial instruments which may result in the acquisition of shares already issued to which voting rights are attached

An acquisition or disposal of instruments with similar economic effect to qualifying financial instruments

An event changing the breakdown of voting rights

ü

Other (please specify):

3. Full name of person(s) subject to thenotification obligation: iii

W. HEALTH LP

4. Full name of shareholder(s)  (if different from 3.):iv

HARGREAVE HALE NOMINEES LIMITED

5. Date of the transaction and date onwhich the threshold is crossed orreached: v

28th JUNE 2017

6. Date on which issuer notified:

28th JUNE 2017

7. Threshold(s) that is/are crossed orreached: vi, vii

49% to 48%

 

8. Notified details:

A: Voting rights attached to shares viii, ix

Class/type ofshares

if possible usingthe ISIN CODE

Situation previousto the triggeringtransaction

Resulting situation after the triggering transaction

NumberofShares

NumberofVotingRights

Numberof shares

Number of votingrights

% of voting rights x

Direct

Direct xi

Indirect xii

Direct

Indirect

 

GB00BYV81293

54,062,901

54,062,901

56,008,541

56,008,541

48.24%

B: Qualifying Financial Instruments

Resulting situation after the triggering transaction

Type of financialinstrument

Expirationdate xiii

Exercise/Conversion Period xiv

Number of votingrights that may beacquired if theinstrument isexercised/ converted.

% of votingrights

C: Financial Instruments with similar economic effect to Qualifying Financial Instruments xv, xvi

Resulting situation after the triggering transaction

Type of financialinstrument

Exercise price

Expiration date xvii

Exercise/Conversion period xviii

Number of voting rights instrument refers to

 

% of voting rights xix, xx

 

 

 

Nominal

Delta

Total (A+B+C)

Number of voting rights

Percentage of voting rights

56,008,541

48.24%

 

9. Chain of controlled undertakings through which the voting rights and/or thefinancial instruments are effectively held, if applicable: xxi

 

Shares held by Hargreave Hale Nominees Limited

 

Proxy Voting:

10. Name of the proxy holder:

N/A

11. Number of voting rights proxy holder will cease to hold:

N/A

12. Date on which proxy holder will cease to hold voting rights:

N/A

13. Additional information:

14. Contact name:

Matthew Edwards (on behalf of W. Health L.P.)

15. Contact telephone number:

0203 620 2000

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
HOLFPMLTMBJTMJR
Date   Source Headline
13th Dec 20223:45 pmRNSSuccessful completion of US$18.5m Equity Fundraise
13th Dec 20227:02 amRNSInvestor presentation
13th Dec 20227:01 amRNSPlacing & Subscription to raise approx. US$18m
13th Dec 20227:00 amRNSCollaborative Sales Agreement signed with Viatris
31st Oct 20227:00 amRNSRepublic of Korea update
27th Oct 20227:00 amRNSShelf-life for Accrufer® extended to 48 months
24th Oct 20227:00 amRNSData presented at ACG Annual Scientific Meeting
30th Sep 20227:00 amRNSBlock Listing 6 Monthly Return
15th Sep 20221:52 pmEQSHardman & Co Research on Shield Therapeutics (STX): Accrufer momentum building
14th Sep 20222:17 pmRNSHolding(s) in Company
8th Sep 20227:00 amRNSHalf-year Report
1st Sep 20222:20 pmRNSHolding(s) in Company
1st Sep 20227:00 amRNSLaunch of new corporate brand and website
31st Aug 20222:00 pmRNSTotal Voting Rights Update
31st Aug 202211:00 amRNSNotice of Interim Results
30th Aug 20229:30 amRNSHolding(s) in Company
12th Aug 202211:45 amEQSHardman & Co: Q&A on Shield Therapeutics (STX): Upside potential is enormous
9th Aug 20224:45 pmRNSGrant of share options
1st Aug 20227:00 amRNSCompletion of Loan Agreement & Partial Conversion
27th Jul 20224:20 pmRNSResults of 2022 General Meeting
27th Jul 20224:15 pmRNSResults of 2022 Annual General Meeting
26th Jul 20227:15 amEQSHardman & Co Research: Shield Therapeutics (STX): Looking to accelerate positive signals in the US
14th Jul 20227:00 amRNSNew Drug Submission accepted by Health Canada
8th Jul 20227:00 amRNSNotice of General Meeting
30th Jun 20224:41 pmRNSSecond Price Monitoring Extn
30th Jun 20224:36 pmRNSPrice Monitoring Extension
30th Jun 20222:06 pmRNSSecond Price Monitoring Extn
30th Jun 20222:00 pmRNSPrice Monitoring Extension
30th Jun 202211:05 amRNSSecond Price Monitoring Extn
30th Jun 202211:00 amRNSPrice Monitoring Extension
30th Jun 20229:05 amRNSSecond Price Monitoring Extn
30th Jun 20229:00 amRNSPrice Monitoring Extension
30th Jun 20227:01 amRNS2021 Annual Report and 2022 AGM Notice
30th Jun 20227:00 amRNSBusiness Update, Final Results&Financing Agreement
29th Jun 20227:00 amRNSNotice of Results
28th Jun 20224:40 pmRNSSecond Price Monitoring Extn
28th Jun 20224:35 pmRNSPrice Monitoring Extension
28th Jun 20222:05 pmRNSSecond Price Monitoring Extn
28th Jun 20222:00 pmRNSPrice Monitoring Extension
29th Apr 20227:00 amRNSTotal Voting Rights Update
31st Mar 20223:50 pmRNSBlock Listing Application
31st Mar 20223:50 pmRNSBlock Listing 6 Monthly Return
21st Mar 20227:00 amRNSKYE Pharmaceuticals Files Accrufer® NDS in Canada
2nd Mar 20221:30 pmEQSHardman & Co Research: Shield Therapeutics (STX) - PBMs have bought in to Accrufer
25th Feb 20227:00 amRNSInvestor Presentation
23rd Feb 20222:06 pmRNSSecond Price Monitoring Extn
23rd Feb 20222:01 pmRNSPrice Monitoring Extension
23rd Feb 202211:05 amRNSSecond Price Monitoring Extn
23rd Feb 202211:00 amRNSPrice Monitoring Extension
18th Feb 20222:06 pmRNSSecond Price Monitoring Extn

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.